• Home  / 
  • Biotech
  •  /  Keryx Biopharmaceuticals (NASDAQ:KERX) Collaborates With BioVectra For Expansion Of Ferric Citrate production

Keryx Biopharmaceuticals (NASDAQ:KERX) Collaborates With BioVectra For Expansion Of Ferric Citrate production

Keryx Biopharmaceuticals (NASDAQ:KERX) has signed a long-term deal with BioVectra Inc to be supplied with Ferric Citrate, the active pharma ingredient used in the Auryxia® tablets, which are used for the treatment of common complications of the chronic kidney condition. BioVentra has a long history of over 45 years of contract development and production experience to the collaboration and has once partnered with Keryx to manufacture the Ferric Citrate API in 2003.

According to the terms of the agreement, BioVectra will set up the anticipated growth of the Ferric Citrate API supply requirements by enhancing the production capacity at their plant in the headquarter facility located in Charlottetown, Prince Edward Island, Canada.

Melissa Bradford-Klug, the chief business officer at Keryx stated that to comply with the latest US FDA approval of the Auryxia for the second study, it’s essential to have the adequate manufacturing capacity to maintain the expected future prescription demand.

According to Oliver Technow, the president at BioVectra, the collaboration between the two firms is the first pivotal step in the journey as the company and is pleased to be granted the opportunity to work closely with the global partners and patients.

Technow also acknowledged that the deal will bring more job opportunities for local people in Charlottetown and it’s a great accomplishment for the entire bioscience region in Canada. Keryx believes that BioVectra is capable of handling the supply of the active pharmaceutical ingredient in Auryxia since they have worked together on the same in 2003.

The partnership shows the capabilities of BioVectra firm. Since Keryx was the first to approach the firm for the proposed clinical supply after nearly 15 years, it illustrates the deep trust and good relationships that Keryx has with BioVectra. In the initial agreement, the two firms partnered on various clinical phases, registration, and commercial supply of the necessary materials. The two companies are looking forward to continuing building their long-term’s strategic supply chain.

About the author

Louisa Hendrickson

Hendrickson is the biotech writer for Investing News Center.

Click here to add a comment

Leave a comment: